NASDAQ:EVFM

Evofem Biosciences Competitors

$1.75
-0.01 (-0.57 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.73
Now: $1.75
$1.79
50-Day Range
$1.71
MA: $2.84
$4.74
52-Week Range
$1.65
Now: $1.75
$6.87
Volume2.14 million shs
Average Volume4.65 million shs
Market Capitalization$145.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.07

Competitors

Evofem Biosciences (NASDAQ:EVFM) Vs. ANAB, ALDX, MRNS, CRNX, IVA, and RIGL

Should you be buying EVFM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Evofem Biosciences, including AnaptysBio (ANAB), Aldeyra Therapeutics (ALDX), Marinus Pharmaceuticals (MRNS), Crinetics Pharmaceuticals (CRNX), Inventiva (IVA), and Rigel Pharmaceuticals (RIGL).

Evofem Biosciences (NASDAQ:EVFM) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Evofem Biosciences and AnaptysBio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-1.34
AnaptysBio$8 million71.39$-97,340,000.00($3.60)-5.80

Evofem Biosciences has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Evofem Biosciences and AnaptysBio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evofem Biosciences01602.86
AnaptysBio13302.29

Evofem Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 471.43%. AnaptysBio has a consensus price target of $30.2857, indicating a potential upside of 45.12%. Given Evofem Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Evofem Biosciences is more favorable than AnaptysBio.

Profitability

This table compares Evofem Biosciences and AnaptysBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evofem BiosciencesN/A-259.47%-111.70%
AnaptysBioN/A-19.09%-17.94%

Volatility & Risk

Evofem Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Institutional & Insider Ownership

44.8% of Evofem Biosciences shares are held by institutional investors. 9.9% of Evofem Biosciences shares are held by company insiders. Comparatively, 13.0% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Evofem Biosciences beats AnaptysBio on 7 of the 12 factors compared between the two stocks.

Evofem Biosciences (NASDAQ:EVFM) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Evofem Biosciences and Aldeyra Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-1.34
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-5.87

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Evofem Biosciences and Aldeyra Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evofem Biosciences01602.86
Aldeyra Therapeutics011002.91

Evofem Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 471.43%. Aldeyra Therapeutics has a consensus price target of $26.00, indicating a potential upside of 115.95%. Given Evofem Biosciences' higher probable upside, equities analysts clearly believe Evofem Biosciences is more favorable than Aldeyra Therapeutics.

Profitability

This table compares Evofem Biosciences and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evofem BiosciencesN/A-259.47%-111.70%
Aldeyra TherapeuticsN/A-73.73%-52.74%

Volatility & Risk

Evofem Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

44.8% of Evofem Biosciences shares are held by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are held by institutional investors. 9.9% of Evofem Biosciences shares are held by company insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aldeyra Therapeutics beats Evofem Biosciences on 8 of the 11 factors compared between the two stocks.

Evofem Biosciences (NASDAQ:EVFM) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Evofem Biosciences and Marinus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-1.34
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($3.96)-3.92

Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Evofem Biosciences and Marinus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evofem Biosciences01602.86
Marinus Pharmaceuticals00903.00

Evofem Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 471.43%. Marinus Pharmaceuticals has a consensus price target of $28.75, indicating a potential upside of 85.24%. Given Evofem Biosciences' higher probable upside, equities analysts clearly believe Evofem Biosciences is more favorable than Marinus Pharmaceuticals.

Profitability

This table compares Evofem Biosciences and Marinus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evofem BiosciencesN/A-259.47%-111.70%
Marinus PharmaceuticalsN/A-95.56%-66.01%

Volatility & Risk

Evofem Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.

Institutional & Insider Ownership

44.8% of Evofem Biosciences shares are held by institutional investors. Comparatively, 79.3% of Marinus Pharmaceuticals shares are held by institutional investors. 9.9% of Evofem Biosciences shares are held by company insiders. Comparatively, 2.8% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Marinus Pharmaceuticals beats Evofem Biosciences on 7 of the 11 factors compared between the two stocks.

Evofem Biosciences (NASDAQ:EVFM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Volatility & Risk

Evofem Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Valuation & Earnings

This table compares Evofem Biosciences and Crinetics Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-1.34
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17

Crinetics Pharmaceuticals has higher revenue and earnings than Evofem Biosciences. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

44.8% of Evofem Biosciences shares are held by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 9.9% of Evofem Biosciences shares are held by company insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Evofem Biosciences and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evofem BiosciencesN/A-259.47%-111.70%
Crinetics PharmaceuticalsN/A-43.35%-39.73%

Analyst Ratings

This is a breakdown of current ratings for Evofem Biosciences and Crinetics Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evofem Biosciences01602.86
Crinetics Pharmaceuticals01302.75

Evofem Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 471.43%. Crinetics Pharmaceuticals has a consensus price target of $35.00, indicating a potential upside of 105.04%. Given Evofem Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Evofem Biosciences is more favorable than Crinetics Pharmaceuticals.

Evofem Biosciences (NASDAQ:EVFM) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Earnings & Valuation

This table compares Evofem Biosciences and Inventiva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-1.34
InventivaN/AN/AN/AN/AN/A

Institutional & Insider Ownership

44.8% of Evofem Biosciences shares are held by institutional investors. Comparatively, 10.5% of Inventiva shares are held by institutional investors. 9.9% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Evofem Biosciences and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evofem BiosciencesN/A-259.47%-111.70%
InventivaN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Evofem Biosciences and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evofem Biosciences01602.86
Inventiva11001.50

Evofem Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 471.43%. Given Evofem Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Evofem Biosciences is more favorable than Inventiva.

Summary

Evofem Biosciences beats Inventiva on 5 of the 7 factors compared between the two stocks.

Evofem Biosciences (NASDAQ:EVFM) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Volatility and Risk

Evofem Biosciences has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Earnings & Valuation

This table compares Evofem Biosciences and Rigel Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem BiosciencesN/AN/A$-80,030,000.00($1.31)-1.34
Rigel Pharmaceuticals$59.29 million9.35$-66,890,000.00($0.40)-8.15

Rigel Pharmaceuticals has higher revenue and earnings than Evofem Biosciences. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

44.8% of Evofem Biosciences shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 9.9% of Evofem Biosciences shares are held by insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Evofem Biosciences and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evofem BiosciencesN/A-259.47%-111.70%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Evofem Biosciences and Rigel Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evofem Biosciences01602.86
Rigel Pharmaceuticals01302.75

Evofem Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 471.43%. Rigel Pharmaceuticals has a consensus target price of $8.3333, indicating a potential upside of 155.62%. Given Evofem Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Evofem Biosciences is more favorable than Rigel Pharmaceuticals.

Summary

Rigel Pharmaceuticals beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.


Evofem Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66-5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04-0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32-0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87-4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28-0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04-5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78-0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00-21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97-0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00-0.3%$502.28 million$58.12 million-16.28
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.72-1.2%$500.13 million$57.49 million-6.49
XBiotech logo
XBIT
XBiotech
1.0$16.95-0.4%$499.33 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87-0.6%$494.21 million$111.75 million-7.63
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.53-6.6%$494.19 millionN/A-2.59Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.90-1.7%$479.24 million$5.80 million-6.48
Akouos logo
AKUS
Akouos
1.6$13.87-1.4%$477.16 millionN/A0.00News Coverage
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.18-2.4%$469.72 million$6.68 million-5.04
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.06-3.3%$469.72 million$335 million-1.03Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.63-3.4%$466.82 million$56.50 million0.00Analyst Upgrade
Gap Up
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.57-4.1%$465.95 million$6.07 million-3.62Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
BCEL
Atreca
1.7$12.29-3.4%$452.65 millionN/A-4.36Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.29-3.1%$452.48 millionN/A0.00Gap Up
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.33-2.3%$449.56 million$102.31 million6.46
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.02-1.4%$446.29 millionN/A0.00News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8N/AN/A$439.81 millionN/A-3.55
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.92-3.9%$438.87 millionN/A-12.08News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
Sesen Bio logo
SESN
Sesen Bio
1.2$2.52-3.2%$426.85 millionN/A-5.73Gap Down
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.45-0.4%$426.64 million$380,000.000.00Analyst Upgrade
DURECT logo
DRRX
DURECT
1.4$1.85-1.6%$420.32 million$29.56 million-36.99
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.66-0.6%$415.41 million$9.48 million-0.28
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$8.26-13.1%$407.75 million$2.42 million-7.25Analyst Report
Unusual Options Activity
Analyst Revision
Gap Up
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$8.12-2.2%$405.38 million$72.96 million-2.63Gap Down
BeyondSpring logo
BYSI
BeyondSpring
1.2$10.29-3.2%$402.77 millionN/A-5.04Gap Down
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.53-4.9%$402.50 million$1.98 million-3.93Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.